A recurrent activating missense mutation in waldenstrom macroglobulinemia affects the DNA binding of the ETS transcription factor SPI1 and enhances proliferation
Published version of a preprint
The DOI matches its Crossref record; 51 of the 52 references it cites were found in a registry or an index.
Abstract
The ETS-domain transcription factors divide into subfamilies based on protein similarities, DNA-binding sequences, and interaction with cofactors. They are regulated by extracellular clues and contribute to cellular processes, including proliferation and transformation. ETS genes are targeted through genomic rearrangements in oncogenesis. The PU.1/SPI1 gene is inactivated by point mutations in human myeloid malignancies. We identified a recurrent somatic mutation (Q226E) in PU.1/SPI1 in Waldenström macroglobulinemia, a B-cell lymphoproliferative disorder. It affects the DNA-binding affinity of the protein and allows the mutant protein to more frequently bind and activate promoter regions with respect to wild-type protein. Mutant SPI1 binding at promoters activates gene sets typically promoted by other ETS factors, resulting in enhanced proliferation and decreased terminal B-cell differentiation in model cell lines and primary samples. In summary, we describe oncogenic subversion of transcription factor function through subtle alteration of DNA binding leading to cellular proliferation and differentiation arrest. Significance: The demonstration that a somatic point mutation tips the balance of genome-binding pattern provides a mechanistic paradigm for how missense mutations in transcription factor genes may be oncogenic in human tumors. This article is highlighted in the In This Issue feature, p. 681
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“in the erythroid lineage, in which SPI1 exerts an oncogenic function by blocking differentiation.”
From HDAC1 and PRC2 mediate combinatorial control in SPI1/PU.1-dependent gene repression in murine erythroleukaemia (2022) · cites this paper as [19]
Citations
Cites
Recurrent Fusion of TMPRSS2 and ETS Transcription Factor Genes in Prostate Cancer
Tomlins, S. A., Rhodes, D. R., Perner, S., Dhanasekaran, S. M., Mehra, R., Sun, X.-W., Varambally, S., Cao, X., Tchinda, J., Kuefer, R., et al. (2005) · Science · doi:10.1126/science.1117679 · Cited by 3,846
Requirement of transcription factor PU.1 in the development of multiple hematopoietic lineages
Scott, E. W., Simon, M. C., Anastasi, J., & Singh, H. (1994) · Science · doi:10.1126/science.8079170 · Cited by 1,532
Oncogenically active MYD88 mutations in human lymphoma
Ngo, V. N., Young, R. M., Schmitz, R., Jhavar, S., Xiao, W., Lim, K.-H., Kohlhammer, H., Xu, W., Yang, Y., Zhao, H., et al. (2011) · Nature · doi:10.1038/nature09671 · Cited by 1,512
MYD88 L265P Somatic Mutation in Waldenström's Macroglobulinemia
Treon, S. P., Xu, L., Yang, G., Zhou, Y., Liu, X., Cao, Y., Sheehy, P., Manning, R. J., Patterson, C. J., Tripsas, C., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200710 · Cited by 1,294
Genetic and functional drivers of diffuse large B cell lymphoma
Reddy, A., Zhang, J., Davis, N. S., Moffitt, A. B., Love, C. L., Waldrop, A., Leppa, S., Pasanen, A., Meriranta, L., Karjalainen-Lindsberg, M.-L., et al. (2017) · Cell · doi:10.1016/j.cell.2017.09.027 · Cited by 1,104
The ETS-domain transcription factor family
Sharrocks, A. D. (2001) · Nature Reviews Molecular Cell Biology · doi:10.1038/35099076 · Cited by 1,086
Mutations driving CLL and their evolution in progression and relapse
Landau, D. A., Tausch, E., Taylor-Weiner, A. N., Stewart, C., Reiter, J. G., Bahlo, J., Kluth, S., Bozic, I., Lawrence, M., Böttcher, S., et al. (2015) · Nature · doi:10.1038/nature15395 · Cited by 1,068
Quivoron, C., Couronné, L., Della Valle, V., Lopez, C. K., Plo, I., Wagner-Ballon, O., Do Cruzeiro, M., Delhommeau, F., Arnulf, B., Stern, M.-H., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.06.003 · Cited by 924
Self-citationOwen, R. G., Treon, S. P., Al-Katib, A., Fonseca, R., Greipp, P. R., McMaster, M. L., Morra, E., Pangalis, G. A., San Miguel, J. F., Branagan, A. R., et al. (2003) · Seminars in Oncology · doi:10.1053/sonc.2003.50082 · Cited by 924
Chromatin-state discovery and genome annotation with ChromHMM
Ernst, J., & Kellis, M. (2017) · Nature Protocols · doi:10.1038/nprot.2017.124 · Cited by 910
Genome-wide analysis of ETS-family DNA-binding in vitro and in vivo
Wei, G., Badis, G., Berger, M. F., Kivioja, T., Palin, K., Enge, M., Bonke, M., Jolma, A., Varjosalo, M., Gehrke, A. R., et al. (2010) · The EMBO Journal · doi:10.1038/emboj.2010.106 · Cited by 568
Exploiting Synthetic Lethality for the Therapy of ABC Diffuse Large B Cell Lymphoma
Yang, Y., Shaffer, A. L., Emre, N. C. T., Ceribelli, M., Zhang, M., Wright, G., Xiao, W., Powell, J., Platig, J., Kohlhammer, H., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.05.024 · Cited by 521
Germinal centres and B cell lymphomagenesis
Basso, K., & Dalla-Favera, R. (2015) · Nature Reviews Immunology · doi:10.1038/nri3814 · Cited by 510
Acute myeloid leukemia induced by graded reduction of a lineage-specific transcription factor, PU.1.
Rosenbauer, F., Wagner, K., Kutok, J. L., Iwasaki, H., Le Beau, M. M., Okuno, Y., Akashi, K., Fiering, S., & Tenen, D. G. (2004) · Nature Genetics · doi:10.1038/ng1361 · Cited by 506
Genomic and biochemical insights into the specificity of ETS transcription factors
Hollenhorst, P. C., McIntosh, L. P., & Graves, B. J. (2011) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.79.081507.103945 · Cited by 490
International prognostic scoring system for Waldenström macroglobulinemia
Morel, P., Duhamel, A., Gobbi, P., Dimopoulos, M. A., Dhodapkar, M. V., McCoy, J., Crowley, J., Ocio, E. M., Garcia-Sanz, R., Treon, S. P., et al. (2009) · Blood · doi:10.1182/blood-2008-08-174961 · Cited by 416
Self-citationAcquired Initiating Mutations in Early Hematopoietic Cells of CLL Patients
Damm, F., Mylonas, E., Cosson, A., Yoshida, K., Della Valle, V., Mouly, E., Diop, M., Scourzic, L., Shiraishi, Y., Chiba, K., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0104 · Cited by 267
Self-citationHeterozygous PU.1 mutations are associated with acute myeloid leukemia
Mueller, B. U., Pabst, T., Osato, M., Asou, N., Johansen, L. M., Minden, M. D., Behre, G., Hiddemann, W., Ito, Y., & Tenen, D. G. (2002) · Blood · doi:10.1182/blood.v100.3.998 · Cited by 243
A library of gene expression signatures to illuminate normal and pathological lymphoid biology
Shaffer, A. L., Wright, G., Yang, L., Powell, J., Ngo, V., Lamy, L., Lam, L. T., Davis, R. E., & Staudt, L. M. (2006) · Immunological Reviews · doi:10.1111/j.0105-2896.2006.00373.x · Cited by 228
Review of Ets1 structure, function, and roles in immunity
Garrett-Sinha, L. A. (2013) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-012-1243-7 · Cited by 213
de la Rica, L., Rodríguez-Ubreva, J., García, M., Islam, A. B., Urquiza, J. M., Hernando, H., Christensen, J., Helin, K., Gómez-Vaquero, C., & Ballestar, E. (2013) · Genome Biology · doi:10.1186/gb-2013-14-9-r99 · Cited by 211
Brass, A. L., Zhu, A. Q., & Singh, H. (1999) · The EMBO Journal · doi:10.1093/emboj/18.4.977 · Cited by 204
Lenz, G., Nagel, I., Siebert, R., Roschke, A. V., Sanger, W., Wright, G. W., Dave, S. S., Tan, B., Zhao, H., Rosenwald, A., et al. (2007) · The Journal of Experimental Medicine · doi:10.1084/jem.20062041 · Cited by 195
Ras/Mitogen-Activated Protein Kinase Signaling Activates Ets-1 and Ets-2 by CBP/p300 Recruitment
Foulds, C. E., Nelson, M. L., Blaszczak, A. G., & Graves, B. J. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.24.10954-10964.2004 · Cited by 190
Ceribelli, M., Kelly, P. N., Shaffer, A. L., Wright, G. W., Xiao, W., Yang, Y., Mathews Griner, L. A., Guha, R., Shinn, P., Keller, J. M., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1411701111 · Cited by 185
Lavallée, V.-P., Baccelli, I., Krosl, J., Wilhelm, B., Barabé, F., Gendron, P., Boucher, G., Lemieux, S., Marinier, A., Meloche, S., et al. (2015) · Nature Genetics · doi:10.1038/ng.3371 · Cited by 172
Nguyen‐Khac, F., Lambert, J., Chapiro, É., Grelier, A., Mould, S. J., Barin, C., Daudignon, A., Gachard, N., Struski, S., Henry, C., et al. (2012) · Haematologica · doi:10.3324/haematol.2012.070458 · Cited by 160
Self-citationThe transcription factors IRF8 and PU.1 negatively regulate plasma cell differentiation
Carotta, S., Willis, S. N., Hasbold, J., Inouye, M., Pang, S. H. M., Emslie, D., Light, A., Chopin, M., Shi, W., Wang, H., et al. (2014) · Journal of Experimental Medicine · doi:10.1084/jem.20140425 · Cited by 155
Quek, L., Otto, G. W., Garnett, C., Lhermitte, L., Karamitros, D., Stoilova, B., Lau, I.-J., Doondeea, J., Usukhbayar, B., Kennedy, A., et al. (2016) · Journal of Experimental Medicine · doi:10.1084/jem.20151775 · Cited by 153
Self-citationPhosphorylation represses Ets-1 DNA binding by reinforcing autoinhibition
Cowley, D. O., & Graves, B. J. (2000) · Genes & Development · doi:10.1101/gad.14.3.366 · Cited by 152
Activating mutations in human acute megakaryoblastic leukemia
Malinge, S., Ragu, C., Della-Valle, V., Pisani, D., Constantinescu, S. N., Perez, C., Villeval, J.-L., Reinhardt, D., Landman-Parker, J., Michaux, L., et al. (2008) · Blood · doi:10.1182/blood-2008-01-136366 · Cited by 145
Self-citationCook, W. D., McCaw, B. J., Herring, C., John, D. L., Foote, S. J., Nutt, S. L., & Adams, J. M. (2004) · Blood · doi:10.1182/blood-2004-06-2234 · Cited by 140
Recurrent SPI1 (PU.1) fusions in high-risk pediatric T cell acute lymphoblastic leukemia
Seki, M., Kimura, S., Isobe, T., Yoshida, K., Ueno, H., Nakajima-Takagi, Y., Wang, C., Lin, L., Kon, A., Suzuki, H., et al. (2017) · Nature Genetics · doi:10.1038/ng.3900 · Cited by 138
Zhang, X., Choi, P. S., Francis, J. M., Gao, G. F., Campbell, J. D., Ramachandran, A., Mitsuishi, Y., Ha, G., Shih, J., Vazquez, F., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0532 · Cited by 126
Gene regulatory networks directing myeloid and lymphoid cell fates within the immune system
Laslo, P., Pongubala, J. M. R., Lancki, D. W., & Singh, H. (2008) · Seminars in Immunology · doi:10.1016/j.smim.2008.08.003 · Cited by 116
Hosokawa, H., Ungerbäck, J., Wang, X., Matsumoto, M., Nakayama, K. I., Cohen, S. M., Tanaka, T., & Rothenberg, E. V. (2018) · Immunity · doi:10.1016/j.immuni.2018.04.024 · Cited by 116
Environmental sensing by mature B cells is controlled by the transcription factors PU.1 and SpiB
Willis, S. N., Tellier, J., Liao, Y., Trezise, S., Light, A., O’Donnell, K., Garrett-Sinha, L. A., Shi, W., Tarlinton, D. M., & Nutt, S. L. (2017) · Nature Communications · doi:10.1038/s41467-017-01605-1 · Cited by 112
Ray-Gallet, D., Mao, C. D., Tavitian, A., & Moreau-Gachelin, F. (1995) · PubMed · Cited by 105
The transcription factor Spi-1/PU.1 binds RNA and interferes with the RNA-binding protein p54nrb
Hallier, M., Tavitian, A., & Moreau-Gachelin, F. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.19.11177 · Cited by 104
John, S. A., Clements, J. L., Russell, L. M., & Garrett-Sinha, L. A. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m705262200 · Cited by 98
The miR-155–PU.1 axis acts on Pax5 to enable efficient terminal B cell differentiation
Lu, D., Nakagawa, R., Lazzaro, S., Staudacher, P., Abreu-Goodger, C., Henley, T., Boiani, S., Leyland, R., Galloway, A., Andrews, S., et al. (2014) · Journal of Experimental Medicine · doi:10.1084/jem.20140338 · Cited by 97
Consequences of the recurrent MYD88L265P somatic mutation for B cell tolerance
Wang, J. Q., Jeelall, Y. S., Beutler, B., Horikawa, K., & Goodnow, C. C. (2014) · The Journal of Experimental Medicine · doi:10.1084/jem.20131424 · Cited by 92
The Transcription Factor Fli-1 Modulates Marginal Zone and Follicular B Cell Development in Mice
Zhang, X. K., Moussa, O., LaRue, A., Bradshaw, S., Molano, I., Spyropoulos, D. D., Gilkeson, G. S., & Watson, D. K. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.3.1644 · Cited by 83
Inhibition of CBP-Mediated Protein Acetylation by the Ets Family Oncoprotein PU.1
Hong, W., Kim, A. Y., Ky, S., Rakowski, C., Seo, S.-B., Chakravarti, D., Atchison, M., & Blobel, G. A. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.11.3729-3743.2002 · Cited by 74
Deregulation of ETS1 and FLI1 contributes to the pathogenesis of diffuse large B-cell lymphoma
Bonetti, P., Testoni, M., Scandurra, M., Ponzoni, M., Piva, R., Mensah, A. A., Rinaldi, A., Kwee, I., Tibiletti, M. G., Iqbal, J., et al. (2013) · Blood · doi:10.1182/blood-2013-01-475772 · Cited by 65
The Transcription Factor GABP Is a Critical Regulator of B Lymphocyte Development
Xue, H., Bollenbacher, J., Wu, Z., Spolski, R. J., Jing, X., Zhang, Y., McCoy, J. P., & Leonard, W. J. (2007) · Immunity · doi:10.1016/j.immuni.2007.03.010 · Cited by 55
DeKoter, R. P., Geadah, M., Khoosal, S., Xu, L. S., Thillainadesan, G., Torchia, J., Chin, S. S., & Garrett-Sinha, L. A. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.1001413 · Cited by 50
Genome-wide comparison of PU.1 and Spi-B binding sites in a mouse B lymphoma cell line
Solomon, L. A., Li, S. K. H., Piskorz, J., Xu, L., & DeKoter, R. P. (2015) · BMC Genomics · doi:10.1186/s12864-015-1303-0 · Cited by 47
Spi-1/PU.1 activates transcription through clustered DNA occupancy in erythroleukemia
Ridinger-Saison, M., Boeva, V., Rimmelé, P., Kulakovskiy, I., Gallais, I., Levavasseur, B., Paccard, C., Legoix-Né, P., Morlé, F., Nicolas, A., et al. (2012) · Nucleic Acids Research · doi:10.1093/nar/gks659 · Cited by 28
Self-citationGenome-Wide Identification of Target Genes for the Key B Cell Transcription Factor Ets1
Saelee, P., Kearly, A., Nutt, S. L., & Garrett‐Sinha, L. A. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00383 · Cited by 28
Hosokawa, H., Ungerbäck, J., Wang, X., Matsumoto, M., Nakayama, K. I., Cohen, S. M., Tanaka, T., & Rothenberg, E. V. (2018) · Immunity · doi:10.1016/j.immuni.2018.09.019 · Cited by 24
Cited by
From multi-omics approaches to personalized medicine in myocardial infarction
Zhan, C., Tang, T., Wu, E., Zhang, Y., He, M., Wu, R., Bi, C., Wang, J., Zhang, Y., & Shen, B. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1250340 · Cited by 72
Lazarian, G., Yin, S., ten Hacken, E., Sewastianik, T., Uduman, M., Font‐Tello, A., Gohil, S. H., Li, S., Kim, E., Joyal, H., et al. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.02.003 · Cited by 57
“Moreover, the same hotspot mutation has been previously identified in diffuse large B cell lymphoma (DLBCL), mantle cell lymphoma and Waldenström’s macroglobulinemia, suggesting its critical role in the malignant transformation of B cells (Bea et al., 2013; Morin et al., 2011; Roos-Weil et al., 2019).”
BackgroundKrzisch, D., Guedes, N. R., Boccon‐Gibod, C., Baron, M., Bravetti, C., Davi, F., Armand, M., Smagghe, L., Caron, J., Bernard, O., et al. (2021) · American Journal of Hematology · doi:10.1002/ajh.26339 · Cited by 49
“Both SPI1 and IKZF3 (3%) mutations were respectively hotspot Q226E and L162R.(13,34) The median number of cytogenetic abnormalities per sample was two (0–22).”
BackgroundResultSelf-citationYao, J., Duan, L., Huang, X., Liu, J., Fan, X., Xiao, Z., Yan, R., Liu, H., An, G., Hu, B., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.769727 · Cited by 47
“Alterations in SPI1 lead to oncogenic subversion by cellular proliferation and differentiation arrest in Waldenström macroglobulinemia (55).”
BackgroundKRAS and RAS-MAPK Pathway Deregulation in Mature B Cell Lymphoproliferative Disorders
Vendramini, E., Bomben, R., Pozzo, F., Bittolo, T., Tissino, E., Gattei, V., & Zucchetto, A. (2022) · Cancers · doi:10.3390/cancers14030666 · Cited by 41
Metadata
- Authors
- Roos-Weil, D., Decaudin, C., Armand, M., Della-Valle, V., Diop, M. K., Ghamlouch, H., Ropars, V., Hérate, C., Lara, D., Durot, E., Haddad, R., Mylonas, E., Damm, F., Pflumio, F., Stoilova, B., Metzner, M., Elemento, O., Dessen, P., Camara-Clayette, V., Cosset, F.-L., Verhoeyen, E., Leblond, V., Ribrag, V., Cornillet-Lefebvre, P., Rameau, P., Azar, N., Charlotte, F., Morel, P., Charbonnier, J.-B., Vyas, P., Mercher, T., Aoufouchi, S., Droin, N., Guillouf, C., Nguyen-Khac, F., & Bernard, O. A.
- Affiliations
- 1INSERM U1170, Gustave Roussy, Villejuif, France.
- Inserm (FR)
- Centre National de la Recherche Scientifique (FR)
- Commissariat à l'Énergie Atomique et aux Énergies Alternatives (FR)
- 10Department of Hematology, Oncology and Tumor Immunology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.
- 9Commissariat à l'Energie Atomique et aux Energies Alternatives (CEA) DSV-IRCM-SCSR-LSHL, Université Paris Diderot Sorbonne Paris Cité, Fontenay-aux-Roses, France.
- University of Oxford (GB)
- Cornell University (US)
- Lyon 1 Université (FR)
- Sorbonne Université (FR)
- 16Laboratoire d'hématologie, Pôle de biologie, CHU de Reims-Hôpital Robert Debré, Avenuedu Général Koenig, Reims, France.
- Centre Hospitalier Universitaire Amiens-Picardie (FR)
- 2Gustave Roussy, Villejuif, France.
- 5Sorbonne Université, Hôpital Pitié-Salpêtrière, APHP, Paris, France.
- Corresponding author
- Bernard, Olivier A.
- ORCID
- Roos-Weil, Damien
- Armand, Marine
- Della-Valle, Véronique
- Diop, M'boyba K.
- Ghamlouch, Hussein
- Ropars, Virginie
- Hérate, Cécile
- Haddad, Rima
- Mylonas, Elena
- Stoilova, Bilyana
- Metzner, Marlen
- Elemento, Olivier
- Dessen, Philippe
- Cosset, François-Loïc
- Verhoeyen, Els
- Leblond, Véronique
- Ribrag, Vincent
- Rameau, Philippe
- Charlotte, Frédéric
- Morel, Pierre
- Charbonnier, Jean-Baptiste
- Vyas, Paresh
- Mercher, Thomas
- Droin, Nathalie
- Guillouf, Christel
- Bernard, Olivier A.
- Venue
- Cancer Discovery
- Published
- 2019-06-01
- Volume
- 9
- Issue
- 6
- Pages
- 796-811
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- OpenAlex
- W2940868784
- Cited by
- 38
- References
- 52
- Citations by year
- 2026: 2 · 2025: 6 · 2024: 2 · 2023: 9 · 2022: 5 · 2021: 8 · 2020: 5 · 2019: 1
- FWCI
- 2.61
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Cancer Discovery (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion)
- Funders
- INSERM INCa (2013-PLBIO-09, 2016-PLBIO-068)
- JTC (2014-143)
- INCa (INCa-DGOS-INSERM_12551, INCA-DGOS-Inserm_12560)
- Association Laurette Fugain
- FRISBI (ANR-10-INBS-05)
- ARC (SFI20111203530)
- MRC (G1000729/94931, MR/L008963/1)
- Ile de France and Fondation de France (00067113)
- Fondation pour la Recherche Médicale
- Topics
- Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
- Health Sciences › Medicine › Pathology and Forensic Medicine › Lymphoma Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics and Chromatin Dynamics
- Keywords
- Waldenström macroglobulinemia, ETS transcription factors, missense mutations, DNA binding affinity, transcriptional activation, B cell proliferation, B cell terminal differentiation, oncogenic transcription factor, somatic mutations, B-cell lymphoproliferative disorders
- MeSH terms
- Lenalidomide, Proto-Oncogene Protein Spi-1, Animals, Azepines, B-Lymphocytes, Base Sequence, Binding Sites, Cell Line, Gene Expression Regulation, Humans, Waldenstrom Macroglobulinemia, Protein Binding, Proto-Oncogene Proteins, Transcription Factors, Triazoles, Trans-Activators, Mutation, Missense, Cell Proliferation, Proto-Oncogene Proteins c-ets, Mice, Myeloid Differentiation Factor 88, Nucleotide Motifs
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.